A cell-cycle phase nonspecific alkylating antineoplastic agent. It is a nitrogen mustard β-chloro-nitrosourea compound. It is used in the treatment of brain tumors and various other malignant neoplasms, Multiple myeloma, Hodgkin’s and Non-Hodgkin’s lymphoma.
Doxorubicin is an anthracycline type of chemotherapy that is used alone or with other chemoagents to treat several different types of cancer.
Bendamustine hydrochloride is a bifunctional chemotherapeutic agent with structurally similar to alkylating agents and purine analogues.
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It has been used in the palliative treatment of Chronic Myeloid Leukemia (CML).
Bortezomib is the first of its class to be approved for clinical use. It is a 26S proteosome inhibitor (26S proteosome is the principal regulator
Hydroxyurea has constantly evolved as a drug ever since its initial approval in CML. The drug has been extensively studied in Acute Leukemias, Sickle Cell Anaemia
Melphalan is an indispensable part of Multiple Myeloma treatment. Being available in oral dosage form, it adds to the convenience of the patient, especially in ‘all oral’ chemotherapy regimens.
Chlorambucil is a classic oral alkylating that was the standard initial treatment of Chronic Lymphocytic Leukemia (CLL) for many years.
Fludarabine is a purine analogue that has replaced traditional alkylating agent based standard initial treatment of Chronic Lymphocytic Leukemia (CLL)